Compare Novartis with ALEMBIC LTD - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NOVARTIS vs ALEMBIC LTD - Comparison Results

NOVARTIS     Change

Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More

ALEMBIC LTD 
   Change

Alembic Limited, in its 99 years of existence, has evolved from being a tincture manufacturer to one of the prominent indigenous pharma companies in India. It is among the top players in the macrolides (anti-infective) and anti-microbials (animal hea... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    NOVARTIS ALEMBIC LTD NOVARTIS/
ALEMBIC LTD
 
P/E (TTM) x 478.0 66.3 721.4% View Chart
P/BV x 27.7 2.4 1,178.1% View Chart
Dividend Yield % 1.6 0.4 380.5%  

Financials

 NOVARTIS   ALEMBIC LTD
EQUITY SHARE DATA
    NOVARTIS
Mar-18
ALEMBIC LTD
Mar-18
NOVARTIS/
ALEMBIC LTD
5-Yr Chart
Click to enlarge
High Rs75872 1,052.8%   
Low Rs57934 1,708.0%   
Sales per share (Unadj.) Rs228.44.7 4,858.6%  
Earnings per share (Unadj.) Rs31.76.1 520.0%  
Cash flow per share (Unadj.) Rs32.86.2 524.6%  
Dividends per share (Unadj.) Rs10.000.20 5,000.0%  
Dividend yield (eoy) %1.50.4 396.0%  
Book value per share (Unadj.) Rs297.140.7 730.8%  
Shares outstanding (eoy) m24.69267.03 9.2%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.911.3 26.0%   
Avg P/E ratio x21.18.7 242.8%  
P/CF ratio (eoy) x20.48.5 240.7%  
Price / Book Value ratio x2.21.3 172.8%  
Dividend payout %31.53.3 961.6%   
Avg Mkt Cap Rs m16,50514,139 116.7%   
No. of employees `0000.7NA-   
Total wages/salary Rs m1,445207 696.9%   
Avg. sales/employee Rs Th8,441.3NM-  
Avg. wages/employee Rs Th2,163.6NM-  
Avg. net profit/employee Rs Th1,173.1NM-  
INCOME DATA
Net Sales Rs m5,6391,255 449.2%  
Other income Rs m1,718370 464.2%   
Total revenues Rs m7,3571,625 452.6%   
Gross profit Rs m-63111 -56.3%  
Depreciation Rs m2538 66.9%   
Interest Rs m552 3,252.9%   
Profit before tax Rs m1,575442 356.5%   
Minority Interest Rs m00-   
Prior Period Items Rs m01,212 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m79224 3,305.2%   
Profit after tax Rs m7841,630 48.1%  
Gross profit margin %-1.18.9 -12.5%  
Effective tax rate %50.35.4 927.0%   
Net profit margin %13.9129.8 10.7%  
BALANCE SHEET DATA
Current assets Rs m9,5221,867 510.0%   
Current liabilities Rs m3,296591 557.5%   
Net working cap to sales %110.4101.6 108.6%  
Current ratio x2.93.2 91.5%  
Inventory Days Days3794 38.8%  
Debtors Days Days2874 38.6%  
Net fixed assets Rs m461,791 2.6%   
Share capital Rs m123534 23.1%   
"Free" reserves Rs m7,21310,324 69.9%   
Net worth Rs m7,33610,858 67.6%   
Long term debt Rs m041 0.0%   
Total assets Rs m11,10511,591 95.8%  
Interest coverage x29.5260.9 11.3%   
Debt to equity ratio x00 0.0%  
Sales to assets ratio x0.50.1 468.9%   
Return on assets %7.614.1 53.7%  
Return on equity %10.715.0 71.2%  
Return on capital %22.215.2 146.3%  
Exports to sales %01.5 0.0%   
Imports to sales %021.0 0.0%   
Exports (fob) Rs mNA19 0.0%   
Imports (cif) Rs mNA263 0.0%   
Fx inflow Rs m6119 312.4%   
Fx outflow Rs m3,630264 1,376.0%   
Net fx Rs m-3,570-244 1,460.4%   
CASH FLOW
From Operations Rs m1,610236 682.7%  
From Investments Rs m687-224 -306.7%  
From Financial Activity Rs m-2,677-27 10,062.0%  
Net Cashflow Rs m-380-15 2,564.9%  

Share Holding

Indian Promoters % 0.0 64.0 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 2.0 0.2 1,000.0%  
FIIs % 1.6 9.7 16.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 21.5 26.1 82.4%  
Shareholders   41,647 54,701 76.1%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare NOVARTIS With:   CADILA HEALTHCARE  TTK HEALTHCARE  ORCHID PHARMA LTD  DISHMAN PHARMA  J.B.CHEMICALS  

Compare NOVARTIS With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 87 Points Higher; Telecom and Auto Stocks Witness Buying(Closing)

Indian share markets ended their trading session marginally higher. On the sectoral front, gains were seen in the telecom sector and auto sector.

Related Views on News

ALEMBIC LTD Announces Quarterly Results (1QFY20); Net Profit Down 70.9% (Quarterly Result Update)

Aug 27, 2019 | Updated on Aug 27, 2019

For the quarter ended June 2019, ALEMBIC LTD has posted a net profit of Rs 20 m (down 70.9% YoY). Sales on the other hand came in at Rs 260 m (down 41.5% YoY). Read on for a complete analysis of ALEMBIC LTD's quarterly results.

NOVARTIS Announces Quarterly Results (1QFY20); Net Profit Down 92.1% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, NOVARTIS has posted a net profit of Rs 8 m (down 92.1% YoY). Sales on the other hand came in at Rs 1 bn (down 20.8% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

NOVARTIS Announces Quarterly Results (4QFY19); Net Profit Down 26.2% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, NOVARTIS has posted a net profit of Rs 195 m (down 26.2% YoY). Sales on the other hand came in at Rs 1 bn (down 11.9% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

ALEMBIC LTD Announces Quarterly Results (4QFY19); Net Profit Down 14.6% (Quarterly Result Update)

May 17, 2019 | Updated on May 17, 2019

For the quarter ended March 2019, ALEMBIC LTD has posted a net profit of Rs 40 m (down 14.6% YoY). Sales on the other hand came in at Rs 253 m (down 23.8% YoY). Read on for a complete analysis of ALEMBIC LTD's quarterly results.

NOVARTIS Announces Quarterly Results (3QFY19); Net Profit Down 31.3% (Quarterly Result Update)

Feb 13, 2019 | Updated on Feb 13, 2019

For the quarter ended December 2018, NOVARTIS has posted a net profit of Rs 129 m (down 31.3% YoY). Sales on the other hand came in at Rs 1 bn (down 13.1% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

More Views on News

Most Popular

Finally, Is the Share Price of Yes Bank Ready for a Rebound?(The 5 Minute Wrapup)

Oct 7, 2019

Here's what every individual investor must know about Yes Bank...

What if Indiabulls Housing Finance and Yes Bank Do Not Rebound?(Profit Hunter)

Oct 1, 2019

How long should you wait for fallen blue chips like Yes Bank and Indiabulls Housing Finance to rebound?

Rebound Riches Could be Yours With These Stocks(Profit Hunter)

Oct 4, 2019

The secret to multibagger is not big businesses, but great managements... Here's how to find them to make the most of once in a decade rebound opportunity.

The One Stock I Like in this Market(The 5 Minute Wrapup)

Oct 10, 2019

There are rare periods in markets when you get good quality stocks at attractive valuations. Is this one such period?

Foreign Money is Chasing Indian Stocks Once Again(The 5 Minute Wrapup)

Oct 4, 2019

Around Rs 75 billion poured into the Indian stock market in the month of September.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

NOVARTIS SHARE PRICE


Oct 14, 2019 (Close)

TRACK NOVARTIS

  • Track your investment in NOVARTIS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

NOVARTIS - SUN PHARMA COMPARISON

COMPARE NOVARTIS WITH

MARKET STATS